funding
Technogenesys, Inc. is undertaking, First-in-man, Phase I clinical trial in mid 2025. It has received funding to run a Phase I Clinical Trial (acronym: PHAROS) from NIH/NCI (RO1 CA286443).
It is currently raising `A’ round of investment to do Phase II clinical trial for (R)-9b inhibitor. Interested parties, VC groups and pharma companies are welcome to get in touch with us. We have extensive dataset which is available for due diligence. Our contact info:
nupam@technogenesys.com
Technogenesys, Inc. is at the forefront of developing `dual’ inhibitor (i) tackling cancer drug resistance, and (ii) activating host immune response
Key reasons for investing in TechnoGenesys:
- We are the first developer of `dual’ prostate cancer drug – a rapidly developing therapeutic area with a huge market
- High unmet medical need: 1.4 million new cases of prostate cancer and over 375,000 related deaths were reported in 2020 globally. Large majority of all cancer related deaths are due to drug resistance
- First-in-class: There are currently no ACK1 inhibitor on the market, and our compound (R)-9b is first in this class.
- De-risked clinical asset with multiple upcoming value inflection points: Initial clinical proof-of-concept expected in Q3, 2025 (First-in-human, Phase I) and completion of phase Ib trial is expected in Q3, 2026
- Highly focused clinical development: Focused early-stage dataset for value creation with opportunities to broaden into 3 other cancer indications (breast and lung cancer)
- Experienced leadership: Leadership team with clear track record from biotech and pharma and a prominent clinical advisory board
- Comprehensive patent protection: We have secured long patent protection (until at least 2035) of our lead asset and we are diligently expanding and strengthening our portfolio of intellectual property rights
